Loading…

Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma

The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM) and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2021-02, Vol.7 (2), p.e06124-e06124, Article e06124
Main Authors: Polyák, Helga, Cseh, Edina Katalin, Bohár, Zsuzsanna, Rajda, Cecilia, Zádori, Dénes, Klivényi, Péter, Toldi, József, Vécsei, László
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3
cites cdi_FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3
container_end_page e06124
container_issue 2
container_start_page e06124
container_title Heliyon
container_volume 7
creator Polyák, Helga
Cseh, Edina Katalin
Bohár, Zsuzsanna
Rajda, Cecilia
Zádori, Dénes
Klivényi, Péter
Toldi, József
Vécsei, László
description The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM) and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type III and IV in MS, representing primary oligodendrogliopathy. To measure the metabolites of the KP in the CPZ treated animals, including TRP, KYN and kynurenic acid (KYNA). We proposed that KYNA levels might be decreased in the CPZ-induced demyelinating phase of the animal model of MS, which model represents the progressive phase of the disease. A total of 64 C57Bl/6J animals were used for the study. Immunohistochemical (IHC) measurements were performed to prove the effect of CPZ, whereas high-performance liquid chromatography (HPLC) was used to quantify the metabolites of the KP (n = 10/4 groups; DEM, CO1, REM, CO2). IHC measurements proved the detrimental effects of CPZ. HPLC measurements demonstrated a decrease of KYNA in the hippocampus (p < 0.05), somatosensory cortex (p < 0.01) and in plasma (p < 0.001). This is the first evidence of marked reduction in KYNA levels in a non-immune mediated model of MS. Our results suggest an involvement of the KP in the pathomechanism of MS, which needs to be further elucidated. Kynurenine pathway; Kynurenic acid; Cuprizone; Multiple sclerosis; Demyelination; Remyelination.
doi_str_mv 10.1016/j.heliyon.2021.e06124
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7f3f109ee444464f8adacf09b41919e3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844021002292</els_id><doaj_id>oai_doaj_org_article_7f3f109ee444464f8adacf09b41919e3</doaj_id><sourcerecordid>2487432995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3</originalsourceid><addsrcrecordid>eNqFUU1vEzEQXSEQrUp_AshHLgn-XO9eQCjio1IlLiBxs2bt2capYwd7N1L49TgkVO0JX2zNvHlvnl_TvGZ0yShr322Wawz-kOKSU86WSFvG5bPmkkuqFp2U9Pmj90VzXcqGUspU1_ZavGwuhFBKaK0vm5-reZf97xSRbCHfowsH4tBmhIKF3B_inDF6S8B6RwLuMRTiI5nWSHJyGCcyZDgWfCkzEoiO7AKULbxqXowQCl6f76vmx-dP31dfF7ffvtysPt4urBJiWowDx47RfmRMCioV01K0Tuqu5VpzYIJTNQC0WnDGrbNCO0UFHUBQhkqBuGpuTrwuwcZUL9XGwSTw5m8h5TsDefI2oNGjGKsUoqynlWMHDuxI-0GynvUoKtf7E9duHrbobLWXITwhfdqJfm3u0t7oTrV150rw9kyQ068Zy2S2vlgMASKmuRguu-qP972qUHWC2pxKyTg-yDBqjiGbjTmHbI4hm1PIde7N4x0fpv5FWgEfToAaFe49ZlOsx2jR-Yx2qt_i_yPxB132u4U</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487432995</pqid></control><display><type>article</type><title>Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma</title><source>Open Access: PubMed Central</source><source>ScienceDirect (Online service)</source><creator>Polyák, Helga ; Cseh, Edina Katalin ; Bohár, Zsuzsanna ; Rajda, Cecilia ; Zádori, Dénes ; Klivényi, Péter ; Toldi, József ; Vécsei, László</creator><creatorcontrib>Polyák, Helga ; Cseh, Edina Katalin ; Bohár, Zsuzsanna ; Rajda, Cecilia ; Zádori, Dénes ; Klivényi, Péter ; Toldi, József ; Vécsei, László</creatorcontrib><description>The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM) and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type III and IV in MS, representing primary oligodendrogliopathy. To measure the metabolites of the KP in the CPZ treated animals, including TRP, KYN and kynurenic acid (KYNA). We proposed that KYNA levels might be decreased in the CPZ-induced demyelinating phase of the animal model of MS, which model represents the progressive phase of the disease. A total of 64 C57Bl/6J animals were used for the study. Immunohistochemical (IHC) measurements were performed to prove the effect of CPZ, whereas high-performance liquid chromatography (HPLC) was used to quantify the metabolites of the KP (n = 10/4 groups; DEM, CO1, REM, CO2). IHC measurements proved the detrimental effects of CPZ. HPLC measurements demonstrated a decrease of KYNA in the hippocampus (p &lt; 0.05), somatosensory cortex (p &lt; 0.01) and in plasma (p &lt; 0.001). This is the first evidence of marked reduction in KYNA levels in a non-immune mediated model of MS. Our results suggest an involvement of the KP in the pathomechanism of MS, which needs to be further elucidated. Kynurenine pathway; Kynurenic acid; Cuprizone; Multiple sclerosis; Demyelination; Remyelination.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2021.e06124</identifier><identifier>PMID: 33553777</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cuprizone ; Demyelination ; Kynurenic acid ; Kynurenine pathway ; Multiple sclerosis ; Remyelination</subject><ispartof>Heliyon, 2021-02, Vol.7 (2), p.e06124-e06124, Article e06124</ispartof><rights>2021 The Author(s)</rights><rights>2021 The Author(s).</rights><rights>2021 The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3</citedby><cites>FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856478/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844021002292$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33553777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polyák, Helga</creatorcontrib><creatorcontrib>Cseh, Edina Katalin</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Rajda, Cecilia</creatorcontrib><creatorcontrib>Zádori, Dénes</creatorcontrib><creatorcontrib>Klivényi, Péter</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><title>Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma</title><title>Heliyon</title><addtitle>Heliyon</addtitle><description>The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM) and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type III and IV in MS, representing primary oligodendrogliopathy. To measure the metabolites of the KP in the CPZ treated animals, including TRP, KYN and kynurenic acid (KYNA). We proposed that KYNA levels might be decreased in the CPZ-induced demyelinating phase of the animal model of MS, which model represents the progressive phase of the disease. A total of 64 C57Bl/6J animals were used for the study. Immunohistochemical (IHC) measurements were performed to prove the effect of CPZ, whereas high-performance liquid chromatography (HPLC) was used to quantify the metabolites of the KP (n = 10/4 groups; DEM, CO1, REM, CO2). IHC measurements proved the detrimental effects of CPZ. HPLC measurements demonstrated a decrease of KYNA in the hippocampus (p &lt; 0.05), somatosensory cortex (p &lt; 0.01) and in plasma (p &lt; 0.001). This is the first evidence of marked reduction in KYNA levels in a non-immune mediated model of MS. Our results suggest an involvement of the KP in the pathomechanism of MS, which needs to be further elucidated. Kynurenine pathway; Kynurenic acid; Cuprizone; Multiple sclerosis; Demyelination; Remyelination.</description><subject>Cuprizone</subject><subject>Demyelination</subject><subject>Kynurenic acid</subject><subject>Kynurenine pathway</subject><subject>Multiple sclerosis</subject><subject>Remyelination</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFUU1vEzEQXSEQrUp_AshHLgn-XO9eQCjio1IlLiBxs2bt2capYwd7N1L49TgkVO0JX2zNvHlvnl_TvGZ0yShr322Wawz-kOKSU86WSFvG5bPmkkuqFp2U9Pmj90VzXcqGUspU1_ZavGwuhFBKaK0vm5-reZf97xSRbCHfowsH4tBmhIKF3B_inDF6S8B6RwLuMRTiI5nWSHJyGCcyZDgWfCkzEoiO7AKULbxqXowQCl6f76vmx-dP31dfF7ffvtysPt4urBJiWowDx47RfmRMCioV01K0Tuqu5VpzYIJTNQC0WnDGrbNCO0UFHUBQhkqBuGpuTrwuwcZUL9XGwSTw5m8h5TsDefI2oNGjGKsUoqynlWMHDuxI-0GynvUoKtf7E9duHrbobLWXITwhfdqJfm3u0t7oTrV150rw9kyQ068Zy2S2vlgMASKmuRguu-qP972qUHWC2pxKyTg-yDBqjiGbjTmHbI4hm1PIde7N4x0fpv5FWgEfToAaFe49ZlOsx2jR-Yx2qt_i_yPxB132u4U</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Polyák, Helga</creator><creator>Cseh, Edina Katalin</creator><creator>Bohár, Zsuzsanna</creator><creator>Rajda, Cecilia</creator><creator>Zádori, Dénes</creator><creator>Klivényi, Péter</creator><creator>Toldi, József</creator><creator>Vécsei, László</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202102</creationdate><title>Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma</title><author>Polyák, Helga ; Cseh, Edina Katalin ; Bohár, Zsuzsanna ; Rajda, Cecilia ; Zádori, Dénes ; Klivényi, Péter ; Toldi, József ; Vécsei, László</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cuprizone</topic><topic>Demyelination</topic><topic>Kynurenic acid</topic><topic>Kynurenine pathway</topic><topic>Multiple sclerosis</topic><topic>Remyelination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polyák, Helga</creatorcontrib><creatorcontrib>Cseh, Edina Katalin</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Rajda, Cecilia</creatorcontrib><creatorcontrib>Zádori, Dénes</creatorcontrib><creatorcontrib>Klivényi, Péter</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polyák, Helga</au><au>Cseh, Edina Katalin</au><au>Bohár, Zsuzsanna</au><au>Rajda, Cecilia</au><au>Zádori, Dénes</au><au>Klivényi, Péter</au><au>Toldi, József</au><au>Vécsei, László</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma</atitle><jtitle>Heliyon</jtitle><addtitle>Heliyon</addtitle><date>2021-02</date><risdate>2021</risdate><volume>7</volume><issue>2</issue><spage>e06124</spage><epage>e06124</epage><pages>e06124-e06124</pages><artnum>e06124</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM) and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type III and IV in MS, representing primary oligodendrogliopathy. To measure the metabolites of the KP in the CPZ treated animals, including TRP, KYN and kynurenic acid (KYNA). We proposed that KYNA levels might be decreased in the CPZ-induced demyelinating phase of the animal model of MS, which model represents the progressive phase of the disease. A total of 64 C57Bl/6J animals were used for the study. Immunohistochemical (IHC) measurements were performed to prove the effect of CPZ, whereas high-performance liquid chromatography (HPLC) was used to quantify the metabolites of the KP (n = 10/4 groups; DEM, CO1, REM, CO2). IHC measurements proved the detrimental effects of CPZ. HPLC measurements demonstrated a decrease of KYNA in the hippocampus (p &lt; 0.05), somatosensory cortex (p &lt; 0.01) and in plasma (p &lt; 0.001). This is the first evidence of marked reduction in KYNA levels in a non-immune mediated model of MS. Our results suggest an involvement of the KP in the pathomechanism of MS, which needs to be further elucidated. Kynurenine pathway; Kynurenic acid; Cuprizone; Multiple sclerosis; Demyelination; Remyelination.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33553777</pmid><doi>10.1016/j.heliyon.2021.e06124</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2021-02, Vol.7 (2), p.e06124-e06124, Article e06124
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7f3f109ee444464f8adacf09b41919e3
source Open Access: PubMed Central; ScienceDirect (Online service)
subjects Cuprizone
Demyelination
Kynurenic acid
Kynurenine pathway
Multiple sclerosis
Remyelination
title Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T09%3A30%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cuprizone%20markedly%20decreases%20kynurenic%20acid%20levels%20in%20the%20rodent%20brain%20tissue%20and%20plasma&rft.jtitle=Heliyon&rft.au=Poly%C3%A1k,%20Helga&rft.date=2021-02&rft.volume=7&rft.issue=2&rft.spage=e06124&rft.epage=e06124&rft.pages=e06124-e06124&rft.artnum=e06124&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2021.e06124&rft_dat=%3Cproquest_doaj_%3E2487432995%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c533t-fb2e8109f114304517436d47862772a13205baa673212cdc37d5030ba301e55a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2487432995&rft_id=info:pmid/33553777&rfr_iscdi=true